WO2024209376 - PROTEIN TYROSINE PHOSPHATASE WEDGE DOMAIN PEPTIDE DIMER FOR NERVOUS SYSTEM REPAIR
National phase entry:
Publication Number
WO/2024/209376
Publication Date
10.10.2024
International Application No.
PCT/IB2024/053264
International Filing Date
03.04.2024
Title **
[English]
PROTEIN TYROSINE PHOSPHATASE WEDGE DOMAIN PEPTIDE DIMER FOR NERVOUS SYSTEM REPAIR
[French]
DIMÈRE PEPTIDIQUE DU DOMAINE DE COIN DE LA PROTÉINE TYROSINE PHOSPHATASE POUR LA RÉPARATION DU SYSTÈME NERVEUX
Applicants **
NERVGEN PHARMA CORP.
112-970 Burrard Street, Unit 1290
Vancouver, British Columbia V6Z 2R4, CA
Inventors
LUKASHEV, Matvey
75 Mechanic Street
Upton, Massachusetts 01568, US
Priority Data
63/493,912
03.04.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CIPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2718 | |
| EPO | Filing, Examination | 26567 | |
| Japan | Filing | 531 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 13435 |
Total: 43826 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The disclosure relates to compositions and methods for nervous system repair. The compositions comprise a peptide that is a dimer, which comprises a first monomer covalently cross-linked with a second monomer, each monomer comprising a domain comprising an amino acid sequence derived from a cytoplasmic wedge domain of a receptor-type protein- tyrosine phosphatase (PTPR). The disclosure also relates to methods and compositions for treating diseases, disorders, and/or conditions associated with inhibition of nervous system repair by chondroitin sulfate proteoglycans (CSPG) or with suppressive effects of LAR family phosphatases, such as PTPRD, PTPRF, and PTPRS on neuro repair.[French]
La divulgation concerne des compositions et des procédés de réparation du système nerveux. Les compositions comprennent un peptide qui est un dimère, qui comprend un premier monomère réticulé de manière covalente avec un second monomère, chaque monomère comprenant un domaine comprenant une séquence d'acides aminés dérivée d'un domaine de coin cytoplasmique d'une protéine-tyrosine phosphatase de type récepteur (PTPR). La divulgation concerne également des procédés et des compositions pour traiter des maladies, des troubles et/ou des états associés à l'inhibition de la réparation du système nerveux par des protéoglycanes de sulfate de chondroïtine (CSPG) ou avec des effets suppresseurs de phosphatases de la famille LAR, tels que PTPRD, PTPRF et PTPRS sur la neuro-réparation.